Rogers Angela, Nesbit M Andrew, Hannan Fadil M, Howles Sarah A, Gorvin Caroline M, Cranston Treena, Allgrove Jeremy, Bevan John S, Bano Gul, Brain Caroline, Datta Vipan, Grossman Ashley B, Hodgson Shirley V, Izatt Louise, Millar-Jones Lynne, Pearce Simon H, Robertson Lisa, Selby Peter L, Shine Brian, Snape Katie, Warner Justin, Thakker Rajesh V
Academic Endocrine Unit (A.R., M.A.N., F.M.H., S.A.H., C.M.G., R.V.T.), Nuffield Department of Clinical Medicine, and Academic Endocrine Unit (A.R., M.A.N., F.M.H., S.A.H., C.M.G., R.V.T.), Radcliffe Department of Medicine, University of Oxford, Oxford OX3 7LJ, United Kingdom; Oxford Molecular Genetics Laboratory (T.C.) and Oxford Centre for Diabetes, Endocrinology, and Metabolism (A.B.G.), Churchill Hospital, Oxford OX3 7LJ, United Kingdom; Department of Paediatric Endocrinology (J.A., C.B.), Great Ormond Street Hospital, London WC1N 3JH, United Kingdom; Department of Paediatric Endocrinology (J.A.), Royal London Hospital, London E1 1BB, United Kingdom; Department of Endocrinology (J.S.B.), Aberdeen Royal Infirmary, Aberdeen AB25 2ZN, United Kingdom; Departments of Diabetes and Endocrinology (G.B.) and Clinical Genetics (S.V.H., K.S.), St George's Hospital, London SW17 0RE, United Kingdom; Jenny Lind Children's Department (V.D.), Norfolk and Norwich University Hospitals National Health Service Foundation Trust, Norfolk NR4 7UY, United Kingdom; Department of Clinical Genetics (L.I.), Guy's and St Thomas' Foundation Trust, Guy's Hospital, London SE1 9RT, United Kingdom; Department of Paediatrics (L.M.-J.), Royal Glamorgan Hospital, Glamorgan CF72 8XR, United Kingdom; Endocrine Unit (S.H.P.), Royal Victoria Infirmary, Newcastle upon Tyne NE1 4LP, United Kingdom; Department of Clinical Genetics (L.R.), Leicester Royal Infirmary, Leicester LE1 5WW, United Kingdom; Department of Medicine (P.L.S.), Manchester Royal Infirmary, Manchester M13 9WL, United Kingdom; Department of Clinical Biochemistry (B.S.), John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom; and Department of Paediatrics (J.W.), University Hospital of Wales, Cardiff CF14 4XW, United Kingdom.
J Clin Endocrinol Metab. 2014 Jul;99(7):E1300-5. doi: 10.1210/jc.2013-3909. Epub 2014 Apr 7.
Autosomal dominant hypocalcemia (ADH) types 1 and 2 are due to calcium-sensing receptor (CASR) and G-protein subunit-α11 (GNA11) gain-of-function mutations, respectively, whereas CASR and GNA11 loss-of-function mutations result in familial hypocalciuric hypercalcemia (FHH) types 1 and 2, respectively. Loss-of-function mutations of adaptor protein-2 sigma subunit (AP2σ 2), encoded by AP2S1, cause FHH3, and we therefore sought for gain-of-function AP2S1 mutations that may cause an additional form of ADH, which we designated ADH3.
The objective of the study was to investigate the hypothesis that gain-of-function AP2S1 mutations may cause ADH3.
The sample size required for the detection of at least one mutation with a greater than 95% likelihood was determined by binomial probability analysis. Nineteen patients (including six familial cases) with hypocalcemia in association with low or normal serum PTH concentrations, consistent with ADH, but who did not have CASR or GNA11 mutations, were ascertained. Leukocyte DNA was used for sequence and copy number variation analysis of AP2S1.
Binomial probability analysis, using the assumption that AP2S1 mutations would occur in hypocalcemic patients at a prevalence of 20%, which is observed in FHH patients without CASR or GNA11 mutations, indicated that the likelihood of detecting at least one AP2S1 mutation was greater than 95% and greater than 98% in sample sizes of 14 and 19 hypocalcemic patients, respectively. AP2S1 mutations and copy number variations were not detected in the 19 hypocalcemic patients.
The absence of AP2S1 abnormalities in hypocalcemic patients, suggests that ADH3 may not occur or otherwise represents a rare hypocalcemic disorder.
常染色体显性低钙血症1型和2型分别由钙敏感受体(CASR)和G蛋白亚基α11(GNA11)的功能获得性突变引起,而CASR和GNA11的功能丧失性突变分别导致家族性低钙尿性高钙血症1型和2型。由AP2S1编码的衔接蛋白2西格玛亚基(AP2σ 2)的功能丧失性突变导致家族性低钙尿性高钙血症3型(FHH3),因此我们寻找可能导致另一种常染色体显性低钙血症(我们将其命名为ADH3)的AP2S1功能获得性突变。
本研究的目的是调查AP2S1功能获得性突变可能导致ADH3这一假说。
通过二项式概率分析确定检测到至少一个突变的可能性大于95%所需的样本量。确定了19例低钙血症患者(包括6例家族性病例),这些患者血清甲状旁腺激素(PTH)浓度低或正常,符合常染色体显性低钙血症,但无CASR或GNA11突变。白细胞DNA用于AP2S1的序列和拷贝数变异分析。
二项式概率分析假设AP2S1突变在低钙血症患者中的发生率为20%(在无CASR或GNA11突变的家族性低钙尿性高钙血症患者中观察到),结果表明,在14例和19例低钙血症患者样本中,检测到至少一个AP2S1突变的可能性分别大于95%和98%。在19例低钙血症患者中未检测到AP2S1突变和拷贝数变异。
低钙血症患者中不存在AP2S1异常,提示可能不存在ADH3,或者它是一种罕见的低钙血症疾病。